We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Interest in MicroRNA Research Driving Growth in Related Market Tools

By LabMedica International staff writers
Posted on 01 Jun 2012
A new study shows that an increased number of pharmaceutical and biotech companies are becoming interested in microRNA (miRNA) research due to advancements in molecular diagnostics and therapeutics. More...
As a result, a larger number of distribution companies are offering miRNA research tools and expanding the spectrum of their applications to cater to a wider range of life science areas.

In a recent study titled Analysis of MicroRNA Tools and Services Market in Europe, Frost & Sullivan (Palo Alto, CA, USA; www.frost.com), a global research and analysis company, examined various miRNA tools and services, including expression profiling and phenotypic screening, to determine that miRNA research is expanding across different fields.

The analysis found that miRNA research has become increasingly prominent in the cardiovascular, virology, endocrinology, plant science, and genetic disease fields. This has caused several other fields to develop an interest in auditing their gene expression analyses or epigenetic research by profiling miRNAs, explained Vinodh Jyotikumar, research consultant, Frost & Sullivan.

As new miRNAs and their functions are discovered, additional research fields may adopt an interest in the role of miRNAs in their disciplines, leading to the need for a wider variety of research tools.

A surge in miRNA research over the past four years has already led several life sciences vendors to offer miRNA research instruments. As competition intensifies, market participants will need to expand and differentiate their product options and capabilities to accommodate a broader range of interested fields.

"Service providers that do not offer in-house technologies must differentiate themselves by expanding tool options or adding capabilities," added Mr. Jyotikumar. "Companies may opt to provide multiple microarrays from various vendors, develop their own tools or offer specialized products, such as multiplex panels aimed at specific diseases."

Analysis of MicroRNA Tools and Services Market in Europe is part of the Frost & Sullivan Clinical Diagnostics Growth Partnership Services program.


Related Links:
Frost & Sullivan


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.